Orally Administered SYN-020 Observed to be Well Tolerated in Healthy Volunteers; A Second Phase 1 Multiple-Ascending Dose Study is on Track to Begin in Q3 2021 ROCKVILLE, Md., June 29, 2021 ...

There is now growing renewed interest in gene therapy as several recent successful clinical trials have now overcome prior technical challenges in the space. Gene therapy involves treating disease by ...

Synthetic Biologics, a biologics and drug development company, has announced its second quarter financial results. Here are three things to know about the company and its financial performance. 1. The ...

Synthetic Biologics has formed a clinical advisory board to support development of SYN-004, its lead anti-infective product candidate for the prevention of the effects of Clostridium difficile. The ...

ROCKVILLE, Md., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (SYN) (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas ...

Synthetic Biologics, a clinical stage company developing therapeutics to protect the gut microbiome, named Isaac J. Bright, MD, vice president, corporate development. 1. Dr. Bright will be responsible ...

-The DSMC has reviewed the safety and pharmacokinetic data from Cohort 1 and recommended that the study may proceed to enroll patients into Cohort 2 - ROCKVILLE, Md., Sept. 27, 2022 (GLOBE NEWSWIRE) - ...

ROCKVILLE, Md., July 15, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of ...

After several tireless days we have finished crunching the numbers from nearly 900 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which ...

Bulletin: ...FLOOD WARNING IN EFFECT UNTIL 315 AM EST MONDAY... * WHAT...Flooding caused by excessive rainfall is expected. * WHERE...A portion of northern New Jersey ...

Acquisition of Rodon Biologics brings operational R&D capability, skilled talent, know-how, drives capital-efficiency, synthetic biology synergy in biopharma. DUBLIN ...